Milnacipran

Speaker 1...and the evidence is fascinating when we look at treatments like milnacipran, an SNRI used for fibromyalgia. It targets those descending monoamine pathways, serotonin and norepinephrine, to help manage chronic pain.

Speaker 2Right. And while alleviating pain is obviously crucial, we’re also exploring how these interventions, and the pain itself, impact long-term health, particularly aging and all-cause mortality.

Speaker 1Exactly. We know unrelieved pain can accelerate biological aging. A GeroScience study from 2025, for example, highlighted that painful diabetic neuropathy is linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy. (PMID 39847262)

Speaker 2So, the core question becomes: does a pain reliever like milnacipran, by reducing chronic pain, also mitigate that accelerated aging and potentially improve longevity? Or are there long-term trade-offs?

Speaker 1That's where the evidence gets complex. While milnacipran can significantly improve quality of life for many, the direct, robust evidence linking its use to a *reduction* in biological aging or *decreased* all-cause mortality is still unestablished.

Speaker 2And importantly, like any medication, milnacipran carries risks. We need to consider potential serious long-term harms like falls, sedation, dependence, or even cardiovascular or GI issues. These could independently affect longevity or quality of life.

Speaker 1Precisely. For individuals genuinely benefiting from milnacipran under medical supervision, its role in pain relief can be vital. However, we simply don’t have clear evidence it *positively* impacts biological aging or all-cause mortality.

Speaker 2So, it's about weighing the known benefits of pain relief against the potential side effects and the current unknowns regarding its broader impact on aging markers. It’s an ongoing area of research.